|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...56575859606162636465666768» |
- thalidomide / Generic mfg.
New P2 trial: THALI-HHT: Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia (clinicaltrials.gov) - Nov 27, 2011
P2, N=31, Recruiting, Sponsor: IRCCS Policlinico S. Matteo
- New P2 trial, Combination therapy: ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Nov 27, 2011
P2, N=35, Recruiting, Sponsor: Vejle Hospital
- | MK-2206 / Merck (MSD)
New P2 trial: Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Nov 27, 2011
P2, N=51, Recruiting, Sponsor: National Cancer Institute (NCI)
- || AZD1480 / AstraZeneca
Enrollment closed, Tumor mutational burden: Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases (clinicaltrials.gov) - Nov 27, 2011
P1, N=65, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting
- ||||||| plerixafor / Generic mfg.
Trial completion, Combination therapy: PREDICT: A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). (clinicaltrials.gov) - Nov 27, 2011
P3, N=118, Completed, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- New P2 trial: Providing Access to Cord Blood Units for Transplants (clinicaltrials.gov) - Nov 22, 2011
P2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
- Rituxan (rituximab) / Roche
Trial termination: Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 22, 2011
P1/2, N=5, Terminated, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Extreme toxicity in Phase I, study did not proceed to Phase II
- Rituxan (rituximab) / Roche
Enrollment change: Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 22, 2011
P1/2, N=5, Terminated, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Terminated; Extreme toxicity in Phase I, study did not proceed to Phase II N=71 --> 5
- Enrollment closed, IO biomarker: Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma (clinicaltrials.gov) - Nov 22, 2011
P=N/A, N=31, Active, not recruiting, Sponsor: Craig Hofmeister
N=71 --> 5 Recruiting --> Active, not recruiting
- ||||||| NovoEight (turoctocog alfa) / Novo Nordisk
Trial completion: guardian (clinicaltrials.gov) - Nov 22, 2011
P3, N=65, Completed, Sponsor: Novo Nordisk
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Empliciti (elotuzumab) / AbbVie, BMS
New P2 trial: Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 21, 2011
P2, N=150, Recruiting, Sponsor: Bristol-Myers Squibb
- | Mekinist (trametinib) / Novartis, BeiGene, afuresertib (LAE002) / Laekna Therap
New P1/2 trial, Combination therapy: A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers (clinicaltrials.gov) - Nov 20, 2011
P1/2, N=20, Completed, Sponsor: GlaxoSmithKline
- ||| prednisone / Generic mfg., lenalidomide / Generic mfg., cyclophosphamide / Generic mfg.
P2 data, Enrollment change: Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Nov 17, 2011
P2, N=70, Active, not recruiting, Sponsor: Indiana University School of Medicine
Active, not recruiting --> Completed N=48 --> 70
- Trial completion: Assessment of Bleeding Symptoms in Normal Individuals Using a Comprehensive History Phenotyping Instrument (clinicaltrials.gov) - Nov 16, 2011
P=N/A, N=412, Completed, Sponsor: Rockefeller University
N=48 --> 70 Active, not recruiting --> Completed
- ||| Farydak (panobinostat) / Secura Bio
Enrollment closed, Combination therapy: MACS1271: Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (clinicaltrials.gov) - Nov 16, 2011
P4, N=55, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P3 trial, Combination therapy: Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Nov 15, 2011
P3, N=200, Recruiting, Sponsor: Ming Hou
- veliparib (ABT-888) / AbbVie
New P1 trial, Combination therapy, PARP Biomarker: Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma (clinicaltrials.gov) - Nov 15, 2011
P1, N=42, Recruiting, Sponsor: Alberta Health Services
- bortezomib / Generic mfg.
Preclinical: Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro (clinicaltrials.gov) - Nov 14, 2011
P=N/A, N=20, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
- ||||| Kovaltry (octocog alfa) / Bayer, CSL Behring
Enrollment change, Head-to-Head: Leopold II: A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A (clinicaltrials.gov) - Nov 14, 2011
P3, N=80, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting N=66 --> 80
- |||| Doptelet (avatrombopag) / SOBI
Trial completion: Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 13, 2011
P2, N=64, Completed, Sponsor: Eisai Inc.
N=66 --> 80 Active, not recruiting --> Completed
- Xyntha (moroctocog alfa) / Pfizer
Trial termination: Study Evaluating The Safety Of Xyntha In Usual Care Settings (clinicaltrials.gov) - Nov 9, 2011
P4, N=12, Terminated, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Terminated; See termination reason in detailed description.
- Xyntha (moroctocog alfa) / Pfizer
Enrollment change: Study Evaluating The Safety Of Xyntha In Usual Care Settings (clinicaltrials.gov) - Nov 9, 2011
P4, N=12, Terminated, Sponsor: Pfizer
Active, not recruiting --> Terminated; See termination reason in detailed description. N=50 --> 12
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, Combination therapy: A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 9, 2011
P3, N=300, Recruiting, Sponsor: AB Science
- Trial completion, Combination therapy: Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma (clinicaltrials.gov) - Nov 8, 2011
P2, N=12, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
N=50 --> 12 Suspended --> Completed
- Enrollment open, Metastases: AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma (clinicaltrials.gov) - Nov 6, 2011
P1, N=60, Recruiting, Sponsor: Craig Hofmeister
Suspended --> Completed Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Roche
Enrollment closed: PLRG4: First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (clinicaltrials.gov) - Nov 2, 2011
P3, N=250, Active, not recruiting, Sponsor: Polish Lymphoma Research Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Jivi (damoctocog alfa pegol) / Bayer
Trial completion: Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration (clinicaltrials.gov) - Nov 2, 2011
P1, N=14, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment open: Incritop: Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=199, Recruiting, Sponsor: Ming Hou
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- simvastatin / Generic mfg.
Trial completion: The Effect of High Dose Simvastatine on Multiple Myeloma (clinicaltrials.gov) - Oct 30, 2011
P1/2, N=10, Completed, Sponsor: Vejle Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- Enrollment change: B-Receptor Signaling in Cardiomyopathy (clinicaltrials.gov) - Oct 30, 2011
P=N/A, N=99, Completed, Sponsor: Daniel Bernstein
Not yet recruiting --> Completed N=300 --> 99
- ||| ulocuplumab (BMS-936564) / BMS
Enrollment open, Combination therapy: Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 30, 2011
P1, N=64, Recruiting, Sponsor: Bristol-Myers Squibb
N=300 --> 99 Not yet recruiting --> Recruiting
- Trial completion: B-Receptor Signaling in Cardiomyopathy (clinicaltrials.gov) - Oct 30, 2011
P=N/A, N=99, Completed, Sponsor: Daniel Bernstein
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Enrollment open: OPTIMS: Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients (clinicaltrials.gov) - Oct 27, 2011
P=N/A, N=100, Recruiting, Sponsor: Bayer
Recruiting --> Completed Not yet recruiting --> Recruiting
- Sylvant (siltuximab) / Jazz
Trial withdrawal, Combination therapy: A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 27, 2011
P3, N=0, Withdrawn, Sponsor: Centocor, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- dexamethasone / Generic mfg., melphalan / Generic mfg., lenalidomide / Generic mfg.
Trial termination: Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma (clinicaltrials.gov) - Oct 27, 2011
P2, N=8, Terminated, Sponsor: New York University School of Medicine
Not yet recruiting --> Withdrawn Active, not recruiting --> Terminated; Due to slow accrual
- | plerixafor / Generic mfg.
Enrollment closed: Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant (clinicaltrials.gov) - Oct 27, 2011
P2, N=40, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Terminated; Due to slow accrual Recruiting --> Active, not recruiting
- bortezomib / Generic mfg., lenalidomide / Generic mfg., sirolimus / Generic mfg.
New P1/2 trial: EMN-alloRIC: Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation (clinicaltrials.gov) - Oct 24, 2011
P1/2, N=45, Active, not recruiting, Sponsor: European Myeloma Network
- New P2 trial: Honey in Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Oct 20, 2011
P2, N=30, Not yet recruiting, Sponsor: mamdouh abdulmaksoud abdulrhman
- sirexatamab (DKN-01) / Leap Therap
New P1 trial, Metastases: A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors (clinicaltrials.gov) - Oct 20, 2011
P1, N=39, Completed, Sponsor: Dekkun Corporation
- |||| Thrombate III (antithrombin III human) / Grifols
Trial completion, Surgery: Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass (clinicaltrials.gov) - Oct 17, 2011
P2, N=200, Completed, Sponsor: Instituto Grifols, S.A.
Recruiting --> Active, not recruiting Recruiting --> Completed
- perifosine (D21266) / AEterna Zentaris
Enrollment closed: Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma (clinicaltrials.gov) - Oct 16, 2011
P=N/A, N=50, Active, not recruiting, Sponsor: AEterna Zentaris
Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- |||| perifosine (D21266) / AEterna Zentaris
Trial completion: Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients (clinicaltrials.gov) - Oct 16, 2011
P1/2, N=84, Completed, Sponsor: Keryx / AOI Pharmaceuticals, Inc.
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- | perifosine (D21266) / AEterna Zentaris
Trial completion: A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstr (clinicaltrials.gov) - Oct 16, 2011
P2, N=37, Completed, Sponsor: AEterna Zentaris
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| perifosine (D21266) / AEterna Zentaris
Trial completion, Combination therapy: Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 16, 2011
P2, N=67, Completed, Sponsor: AEterna Zentaris
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change, Surgery: INWOUND: Wound Healing Abnormalities in Major Abdominal Surgery (clinicaltrials.gov) - Oct 13, 2011
P=N/A, N=200, Recruiting, Sponsor: Klinikum St. Georg gGmbH
Active, not recruiting --> Completed N=260 --> 200
- Trial completion: Non-Ablative Allo HSCT For Hematologic Malignancies or SAA (clinicaltrials.gov) - Oct 12, 2011
P2, N=58, Completed, Sponsor: Case Comprehensive Cancer Center
N=260 --> 200 Active, not recruiting --> Completed
- Bexxar (iodine I 131 tositumomab) / GSK
Enrollment closed: Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 10, 2011
P1, N=40, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- bortezomib / Generic mfg., melphalan / Generic mfg.
Trial completion: Velcade (clinicaltrials.gov) - Oct 10, 2011
P2, N=61, Completed, Sponsor: University Hospital, Toulouse
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment open: The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass (clinicaltrials.gov) - Oct 4, 2011
P4, N=100, Recruiting, Sponsor: Maine Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Bexxar (iodine I 131 tositumomab) / GSK
Enrollment closed: Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 4, 2011
P2, N=140, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting